Navigation Links
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Date:10/18/2007

pathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy.

About Schering-Plough

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for boceprevir. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details and a discussion of risks and uncertainties that may impact
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
5. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
6. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Champions Biotechnology, Inc . (OTC Bulletin Board: CSBR), ... preclinical platforms and tumor specific data to enhance ... financial results for the second fiscal quarter ended ... financial results are available in the Company,s Form ... for the second quarter of 2010 were $1,289,000 ...
(Date:12/15/2009)... 15 The U.S. Food and Drug Administration ... voted 12 yes, 4 no, and 1 abstention that ... risks to support the use of CRESTOR® (rosuvastatin calcium) ... greater than or equal to 50 years, women greater ... LDL < 130 mg/dL; hsCRP greater than or equal ...
(Date:12/15/2009)... -- Dakim, Inc. and Alzheimer,s Weekly today announced the ... Health Contest, designed to help five seniors in their ... disease. All five winners will receive a $2,500 Dakim ... seniors preserve their brain health and the most widely ... across the country. ,, The contest, held ...
Breaking Medicine Technology:Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 55 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3ImaginAb Inc and BZL Biologics LLC Conclude Licensing Agreement for Imaging Rights to huJ591 Prostate Specific Membrane Antigen 28PSMA 29 14433 1ImaginAb Inc and BZL Biologics LLC Conclude Licensing Agreement for Imaging Rights to huJ591 Prostate Specific Membrane Antigen 28PSMA 29 14433 2Aprimas EHR Helps Bend Urology Associates Improve Efficiency Workflow 5391 1Aprimas EHR Helps Bend Urology Associates Improve Efficiency Workflow 5391 2Aprimas EHR Helps Bend Urology Associates Improve Efficiency Workflow 5391 3Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 1Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 2Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 3Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 4Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 5Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 6Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 7Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 8Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 9
... 10 Diplomat Specialty,Pharmacy announced today that Teva ... of only three sites to participate in a ... (TOP MS)., The goal, of the two ... benefits of a,specialty pharmacy therapy management program on ...
... Medical,Innovations, Inc. (Amex: IMA ), a ... management solutions, met yesterday with,Ban Ki-moon, the ... of a,group of senior executives of seventeen ... and diagnostic companies.,Inverness, together with senior officials ...
Other Medicine Technology:Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3
(Date:12/15/2009)... of the U.S. Senate to allow importation of ... more effective direct bulk purchasing of prescription drugs, ... industry controls the health reform debate, according Consumer ... Dorgan (D-ND) was a relatively modest proposal, far ... to directly negotiate discounts with drug manufacturers," said ...
(Date:12/15/2009)... SUNNYVALE, Calif., Dec. 15 Palo Alto ... Shinshu University has deployed its PA-4000 Series next-generation ... network and for enhanced visibility and control over ... University is a Japanese national university with eight ... in 1949 by integrating a number of academic ...
(Date:12/15/2009)... where all couples of reproductive age were evaluated, Italian ... The number of children born with cystic fibrosis decreases ... mutation carriers increases, a new study finds. , CF ... northeast Italy for many years. Since the 1990s, the ... number of infants born with CF. , Two different ...
(Date:12/15/2009)... cancer tests promised but not delivered ,, ... calls on Congress to ensure that healthcare reform ... currently required of insurance companies in 37 states. ... those segments of the population and individuals who ... men and men who have a family history ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will ... "it doesn,t matter whether there,s a public option. The ... option - give government authority over how your doctor ... social agenda by shifting billions of dollars from Medicare ... and local politicians." ,, Betsy McCaughey is ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... Cancer Society (SCS) Singapore have started a month-long prostate screening ... to reach out to more Singaporean men between the ages ... the warning signs of prostate disease and encourage early treatment. ... Awareness Month said: “Prostate disease affects up to half of ...
... the setbacks the Novartis seems to be receiving in its ... that the US Patent// and Trademark Office has made a ... stem cells granted in the last few years. ,Patent ... on the works of James A.Thomson of the University of ...
... Chronic constipation affects 15 to 20 percent of the ... defecation, in which muscles used// for bowel movements do ... be relieved now, as the new research shows biofeedback ... was better than standard treatment of laxatives, diet and ...
... may boost the likelihood of heart problems in high ... studies have suggested that ibuprofen interferes with the effects ... cardiovascular health over one year of more than 18,000 ... patients were taking part in the Therapeutic Arthritis Research ...
... have carried out the world's first successful heart surgery to ... operation was performed at Siriraj Hospital on February 20 by ... than 50 days later the separated twins were still in ... the world that doctors have successfully separated Siamese twins joined ...
... antigen (PSA) in a man’s bloodstream at the time ... change over the course of the disease// does not ... in the April 4 Journal of the National Cancer ... cancer have high long-term survival rates, many patients undergo ...
Other Medicine News:Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Painkiller may Boost Chance of Heart Problems in Patients With Osteoarthritis 2Health News:PSA Not a Good Predictor of Lethal Prostate Cancer 2
... The biokitHSV-2 Rapid Test is a single ... in heparinized capillary whole blood taken by ... specific for herpes simplex virus type 2 ... with HSV-2. It is intended for in-vitro ...
... is the first compact, broad menu clinical ... in any treatment setting. Care givers can ... with less than one minute of hands-on ... in quality to larger, expensive laboratory analyzers ...
The GelPort XE hand access system combines the technology of the GelSeal® cap with the retraction and protection of the Alexis wound retractor....
The CPAP TREND 110 delivers performance with quiet operation. Can be used together with the SomnoPlus CPAP Mask and AquaTrend Heated Humidifier....
Medicine Products: